VIDEO: Using JAK inhibitors in combination with conventional synthetic DMARDs

Editor's note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

The answer, I would say, overwhelmingly is a yes. So specifically talking about first, rheumatoid arthritis, you know, the usual, there's a kind of a hierarchy about how do we go about treating a patient with rheumatoid arthritis. We, of course, always start with conventional synthetic DMARDs, and if a patient is not responding, you either add on, but especially if they have poor prognostic factors such as, you know, erosive disease of overwhelmingly seropositive virologies in the patient, inflammatory presentation from the get-go for rheumatoid arthritis, then in such a patient I would go on to, like, a targeted synthetic DMARD, biologic DMARD, earlier, than just keep rotating conventional DMARDs. So definitely we will add them on to the prior conventional synthetic DMARD. So that's, for sure, a combination we do.

Same holds true for like, psoriatic arthritis. From a rheumatologist perspective, I can attest to their combination being in the rheumatologic world, but not sure a hundred percent what dermatologists do, but at least from rheumatology, we do do the combination. I personally have not combined TS DMARD, like a JAK inhibitor, with a biologic DMARD, so that, I don't think, is a much widely practiced combination, but for sure we combine JAK inhibitors with conventional synthetic DMARDs.